This commentary proposes a hybrid drug pricing reform model balancing most favored nation (MFN) benchmarking with domestic negotiation strategies that drive equity-focused valuation frameworks.
Franklyn Rocha Cabrero, MD
Advertisement
Articles by Franklyn Rocha Cabrero, MD
Advertisement
Latest Updated Articles
Repricing Fairly: Balancing MFN and Domestic ReformsDecember 2nd 2025
Advertisement
Advertisement
Trending on AJMC
1
Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home
2
Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS
3
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
4
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
5